text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 121268-17-5 | Product Number: A2456

Alendronate Sodium Trihydrate


Purity: >97.0%(T)
Synonyms:
  • Alendronic Acid Monosodium Salt Trihydrate
  • (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonic Acid Monosodium Salt Trihydrate
  • Monosodium (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonate Trihydrate
Documents:
5G
€ 87,00
14   ≥40 
25G
€ 200,00
3   25  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number A2456
Purity / Analysis Method >97.0%(T)
Molecular Formula / Molecular Weight C__4H__1__2NNaO__7P__2·3H__2O = 325.13  
Physical State (20 deg.C) Solid
Storage Temperature <0°C
Condition to Avoid Heat Sensitive
CAS RN 121268-17-5
Related CAS RN 66376-36-1&129318-43-0
Reaxys Registry Number 6947932
PubChem Substance ID 135727181
Merck Index (14) 229
MDL Number

MFCD01748233

Specifications
Appearance White to Almost white powder to crystal
Purity(Neutralization titration) min. 97.0 %
Drying loss 16.1 to 17.1 %
Properties (reference)
Solubility in water Slightly soluble
Solubility (very slightly) Alcohol
Solubility (insoluble in) Chloroform
GHS
Related Laws:
RTECS# SZ6523666
Transport Information:
HS Number 2931399090
Application
Studies of Alendronate Biological Actions
References

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

M. Sato, W. Grasser, N. Endo, R. Akins, H. Simmons, D. D. Thompson, E. Golub, G. A. Rodan, J. Clin. Invest. 1991, 88, 2095.

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

J. E. Fisher, M. J. Rogers, J. M. Halasy, S. P. Luckman, D. E. Hughes, P. J. Masarachia, G. Wesolowski, R. G. G. Russell, G. A. Rodan, A. A. Reszka, Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 133.

Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies

M. Neves, L. Gano, N. Pereira, M. C. Costa, M. R. Costa, M. Chandia, M. Rosado, R. Fausto, Nucl. Med. Biol. 2002, 29, 329.

Synthesis and Study of Alendronate Derivatives as Potential Prodrugs of Alendronate Sodium for the Treatment of Low Bone Density and Osteoporosis

P. Vachal, J. J. Hale, Z. Lu, E. C. Streckfuss, S. G. Mills, M. MacCoss, D. H. Yin, K. Algayer, K. Manser, F. Kesisoglou, S. Ghosh, L. L. Alani, J. Med. Chem. 2006, 49, 3060.


Application
Bone Resorption Inhibitors
References

1)Anti-bone resorption

a)J. E. Dunford, K. Thompson, F. P. Coxon, S. P. Luckman, F. M. Hahn, C. D. Poulter, F. H. Ebetino, M. J. Rogers., J. Pharmacol. Exp. Ther. 2001, 296, 235. b)E. Hiroi-Furuya, T. Kameda, K. Hiura, H. Mano, K. Miyazawa, Y. Nakamaru, M. Watanabe-Mano, N. Okuda, J. Shimada, Y. Yamamoto, Y. Hakeda, M. Kumegawa, Calcif. Tissue Int. 1999, 64, 219.

b)E. Hiroi-Furuya, T. Kameda, K. Hiura, H. Mano, K. Miyazawa, Y. Nakamaru, M. Watanabe-Mano, N. Okuda, J. Shimada, Y. Yamamoto, Y. Hakeda, M. Kumegawa, Calcif. Tissue Int. 1999, 64, 219.


PubMed Literature


Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Analytical Charts
Please enter Lot Number Incorrect Lot Number is entered

The requested analytical chart is not available. Sorry for the inconvenience.

Other Documents